Detalle Publicación

STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts

Autores: Avalle, L. (Autor de correspondencia); Raggi, L.; Monteleone, E.; Savino, A.; Viavattene, D.; Statello, Luisa; Camperi, A.; Aversano Stabile, S.; Salemme, V.; De Marzo, N.; Marino, F.; Guglielmi, C.; Lobascio, A.; Zanini, C.; Forni, M.; Incarnato, D.; Defilippi, P.; Oliviero, S.; Poli, V. (Autor de correspondencia)
Título de la revista: ONCOGENE
ISSN: 0950-9232
Volumen: 41
Número: 10
Páginas: 1456 - 1467
Fecha de publicación: 2022
In the tumor microenvironment, Cancer Associated Fibroblasts (CAFs) become activated by cancer cells and increase their secretory activity to produce soluble factors that contribute to tumor cells proliferation, invasion and dissemination to distant organs. The pro-tumorigenic transcription factor STAT3 and its canonical inducer, the pro-inflammatory cytokine IL-6, act conjunctly in a positive feedback loop that maintains high levels of IL-6 secretion and STAT3 activation in both tumor and stromal cells. Here, we demonstrate that STAT3 is essential for the pro-tumorigenic functions of murine breast cancer CAFs both in vitro and in vivo, and identify a STAT3 signature significantly enriched for genes encoding for secreted proteins. Among these, ANGPTL4, MMP13 and STC-1 were functionally validated as STAT3-dependent mediators of CAF pro-tumorigenic functions by different approaches. Both in vitro and in vivo CAFs activities were moreover impaired by MMP13 inhibition, supporting the feasibility of a therapeutic approach based on inhibiting STAT3-induced CAF-secreted proteins. The clinical potential of such an approach is supported by the observation that an equivalent CAF-STAT3 signature in humans is expressed at high levels in breast cancer stromal cells and characterizes patients with a shorter disease specific survival, including those with basal-like disease.